The South African Health Products Regulatory Authority (SAHPRA) is advocating for the usage of the MedSafety app as a means of bolstering efforts to ensure the integrity of medicinal products. #MedSafetyWeek is a global campaign that aims to improve the safety of medications all around the world, and this project is a component of that campaign. The campaign, involving more than 80 regulatory agencies, is a testament to the collective effort to better the healthcare industry.
Â
Patients, physicians, nurses, and pharmacists are all able to report adverse effects with the help of a powerful tool called the MedSafety app. These reports are absolutely necessary for the continuous monitoring of the medications’ safety. According to Mafora Matlala, the Pharmacovigilance Manager at SAHPRA, “Every report is important in building more knowledge and understanding of the benefits and risks of medicines in clinical use and allows action to be taken to minimise risks.”
Users can download the MedSafety app from the Google Play Store or the Apple App Store, depending on your device. The app allows users to report adverse events and product quality issues. This helps enhance the safety of the healthcare environment overall.
SAHPRA’s commitment to the safety, efficacy, and quality of all health products underlines its ethos. Together, we can make a difference in ensuring safer medicines for all.
🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.
A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.
#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1
💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?
A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.
Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.
#SyenzaNews #HealthEconomics #MarketAccess
🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?
This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.
Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!
#SyenzaNews #HealthEconomics #Innovation #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
